Spectrum and frequency of BRCA1, BRCA2, CHEK2, PALB2, RAD50 mutations in breast cancer patients in the Republic of Bashkortostan

Abstract

Aim. To assess the spectrum and frequency of mutations in patients with hereditary breast cancer from the Republic of Bashkortostan.

Methods. The material for the study was sections of fresh frozen, formalin-fixed and paraffin-embedded tumor tissue from 100 unrelated patients with a histologically confirmed diagnosis of breast cancer. The study was carried out using two methods: real-time polymerase chain reaction and next-generation sequencing-NGS.

Results. By using real-time polymerase chain reaction (PCR), the 5382insC mutation in the BRCA1 gene was detected in 12 cases. By using a next-generation sequencing method (NGS), highly penetrant mutations in BRCA1, BRCA2, CHEK2, PALB2 and RAD50 were revealed in 16 patients. In total, these methods detected mutations in 28 patients. Out of a total of probands in the BRCA1 gene, mutations were detected in 13 patients, that included 12 patients with the 5382insC mutation, and 1 patient with c.3143delG. In the BRCA2 gene, mutations were revealed in 3 patients, of which c.6621_6622del in 2 patients and c.-39-1_-39delGA in 1 patient. Mutations in CHEK2 were detected in 5 patients: c.470T>C in 3 patients, c.444+1G>A in 2 patients. The 1592delT mutation in PALB2 was found in 4 patients. The c.2157delA mutation in RAD50 was detected in 3 patients.

Conclusion. Pathogenic mutations in BRCA1/2, CHEK2, PALB2 and RAD50 were found in 28 patients with a hereditary feature of the disease; the identification of highly penetrant mutations in probands allowed us to determine their relatives, probable carriers of mutations, which were referred for genetic counselling.

Keywords

breast cancer / diagnostics / mutation / genes BRCA1 / BRCA2 / CHEK2 / PALB2 / RAD50

References

[1] Sostoyanie onkologicheskoy pomoshchi naseleniyu Rossii v 2018 godu. (The status of cancer care for the population of Russia in 2018.) A.D. Kaprin, V.V. Starinskiy, G.V. Petrova eds. М.: MNIIOI named by P.A. Herzen. 2019; 236 р. (In Russ.)

[2] Состояние онкологической помощи населению России в 2018 году. Под. ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена. 2019; 236 с.

[3] Bochkova N.P., Ginter E.K., Puzireva E.P. Nasledstvennye bolezni. Natsional'noe rukovodstvo. (Inherited Diseases. National Guidelines.) М.: GEOTAR-Media. 2013; 936 р. (In Russ.)

[4] Бочкова Н.П., Гинтер Е.К., Пузырёва Е.П. Наследственные болезни. Национальное руководство. М.: ГЭОТАР-Медиа. 2013; 936 с.

[5] Onkologiya (Oncology). D. Kaschiato ed. М.: Praktika. 2008; 1039. (In Russ.)

[6] Онкология. Под ред. Д. Касчиато. М.: Практика. 2008; 1039 с.

[7] Musin Sh.I., Sultanbaeva N.I., Nasretdinov A.F. et al. Determination of high penetrant mutations in breast cancer patients. Norvegian J. Develop. Intern. Sci. 2020; (42-2): 56–59. (In Russ.)

[8] Мусин Ш.И., Султанбаева Н.И., Насретдинов А.Ф. и др. Определение высокопенетрантных мутаций у больных раком молочной железы. Norvegian J. Develop. Intern. Sci. 2020; (42-2): 56–59.

[9] Sakaeva D.D., Sultanbaev A.V., Sultanbaeva N.I., Popova E.V. Primary multiple metachronous breast cancer and ovarian cancer: diagnosis and treatment. Effektivnaya farmakotera­piya. 2019; 15 (3): 10–17. (In Russ.)

[10] Сакаева Д.Д., Султанбаев А.В., Попова Е.В., Султанбаева Н.И. Первично-множественный рак молочной железы и рак яичников: диагностика и лечение. Эффективн. фармакотерап. 2019; 15 (3): 10–17.

[11] Novikova E.I., Snigireva G.P., Telysheva G.N et al. Molecular genetic diagnosis of hereditary breast cancer and ovarian cancer. In: Opu­kholevye markery: molekulyarno-geneticheskie i klinicheskie aspekty. (Tumor markers: molecular genetic and clinical aspects.) Novosibirsk: Novosibirsk national research state university. 2019; 39–41. (In Russ.)

[12] Новикова Е.И., Снигирёва Г.П., Телышева Г.Н. и др. Молекулярно-генетическая диагностика наследственного рака молочной железы и рака яичников. В кн.: Опухолевые маркёры: молекулярно-генетические и клинические аспекты. Новосибирск: Новосибирский нац. исслед. гос. ун-т. 2019; 39–41.

[13] Farmer H., Cabe N., Lord C.J. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic stra­tegy. Nature. 2005. 434; (7035): 917–921. DOI: 10.1038/nature 03445.

[14] Robson M., Seock-Ah Im, Senkus E. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med. 2017; 377: 523–533. DOI: 10.1056/NEJMoa1706450.

[15] Snigireva G.P., Rumyantseva V.A., Novikova E.I., Novitskaya N.N. Algorithm of molecular genetic investigation to identify hereditary BRCA-­associated breast cancer. Almanakh klinicheskoy meditsini. 2019; 47 (1): 54–65. (In Russ.) DOI: 10.18786/2072-0505-2019-47-002.

[16] Снигирёва Г.П., Румянцева В.А., Новикова Е.И. и др. Алгоритм молекулярно-генетического обследования для выявления наследственного BRCA-ассоциированного рака молочной железы. Альманах клин. мед. 2019; 47 (1): 54–65. DOI: 10.18786/2072-0505-2019-47-002.

[17] Novikova E.I., Snigiryova G.P. Next-generation sequencing (NGS): application in molecular genetic studies in oncology. Vestnik of the russian scientific center of roentgenoradiology. 2016; 16 (1): 6. (In Russ.)

[18] Новикова Е.И., Снигирёва Г.П. Секвенирование «нового поколения» (NGS): применение для молекулярно-генетических исследований в онкологии. Вестн. Рос. науч. центра рентгенорадиол. 2016; 16 (1): 6.

[19] Grudinina N.A., Golubkov V.I., Tikhomirova O.S. et al. Prevalence of widespread BRCA1 gene mutations in patients with familial breast cancer from St. Petersburg. Russian journal of genetics. 2005; 41 (3): 318–322. (In Russ.) DOI: 10.1007/s11177-005-0091-z.

[20] Грудинина Н.А., Голубков В.И., Тихомирова О.С. и др. Преобладание широко распространённых мутаций в гене BRCA1 у больных семейными формами рака молочной железы Санкт-Петербурга. Гене­тика. 2005; 41 (3): 405–410. DOI: 10.1007/s11177-005-0091-z.

[21] Iyevleva A.G., Suspitsin E.N., Kroeze K. et al. Non-founder BRCA1 mutations in Russian breast cancer patients. Cancer Lett. 2010; 298: 258–263. DOI: 10.1016/j.canlet.2010.07.013.

[22] Shubin V.P., Karpukhin A.V. Molecular genetics of inherit predisposition to ovarian cancer. Meditsinskaya genetika. 2011; 10 (4): 39–47. (In Russ.)

[23] Шубин В.П., Карпухин А.В. Молекулярная генетика наследственной предрасположенности к раку яичников. Мед. генет. 2011; 10 (4): 39–47.

[24] Domagala P., Wokolorczyk C., Cybulski C. et al. Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer. Breast Cancer Res. Treat. 2012; 132 (3): 937–945. DOI: 10.1007/s10549-011-1635-7.

[25] Muranen T.A., Blomqvist C., Dörk T. et al. Patient survival and tumor characteristics associated with CHEK2:p.I157T — findings from the Breast Cancer Association Consortium. Breast Cancer Res. 2016; 18 (1): 98. DOI: 10.1186/s13058-016-0758-5.

[26] Huszno J., Budryk M., Kołosza Z. et al. Compa­rison between CHEK2*1100delC/I157T Mutation car­rier and noncarrier breast cancer patients: A clinicopa­thological analysis. Oncology. 2016; 90 (4): 193–198. DOI: 10.1159/000444326.

[27] Bell D.W., Varley J.M., Szydlo T.E. et al. Hetero­zygous germ line CHEK2 mutations in Li-Fraumeni syndrome. Science. 1999; 286 (5449): 2528–2531. DOI: 10.1126/science.286.5449.2528.

[28] Yang X., Leslie G., Doroszuk A. et al. Cancer risks associated with germline PALB2 pathogenic variants: An international study of 524 families. J. Clin. Oncol. 2020; 38 (7): 674–685. DOI: 10.1200/JCO.19.01907.

[29] Leyton Y., Gonzalez-Hormazabal P., Blanco R. et al. Association of PALB2 sequence variants with the risk of familial and early-onset breast cancer in a South-Ame­rican population. BMC Cancer. 2015; 31 (15 (1)): 30. DOI: 10.1186/s12885-015-1033-3.

[30] Heikkinen K., Rapakko K., Karppinen S.M. et al. RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis. 2006; 27: 1593–1599. DOI: 10.1093/carcin/bgi360.

[31] Tommiska J., Seal S., Renwick A. et al. Evaluation of RAD50 in familial breast cancer predisposition. Int. J. Cancer. 2006; 118: 2911–2916. DOI: 10.1002/ijc.21738.

[32] Uhrhammer N., Delort L., Bignon Y.J. Rad50 c.687delT does not contribute significantly to familial breast cancer in a French population. Cancer Epidemiol. Biomarkers Prev. 2009; 18: 684–685. DOI: 10.1158/1055-9965.EPI-08-0971.

[33] Cao A.Y., Hu Z., Yin W.J. et al. Some common mutations of RAD50 and NBS1 in western populations do not contribute significantly to Chinese non-BRCA1/2 here­ditary breast cancer. Breast Cancer Res. Treat. 2010; 121: 247–249. DOI: 10.1007/s10549-009-0629-1.

[34] Kwong A., Shin V.Y., Ho J.C.W. et al. Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries. J. Med. Genet. 2016; 53: 15–23. DOI: 10.1136/jmedgenet-2015-103132.

RIGHTS & PERMISSIONS

Pushkarev A.V., Sultanbaeva N.I., Pushkarev V.A., Nasretdinov A.F., Menshikov K.V., Musin S.I., Minniakhmetov I.R., Gilyazova I.R., Izmailov A.A., Sultanbaev A.V.